Evidence supporting the use of: Immunoglobulin G
For the health condition: Measles
Synopsis
Source of validity: Scientific
Rating (out of 5): 4
Immunoglobulin G (IgG), often administered as immune globulin preparations, has a well-established role in the post-exposure prophylaxis and sometimes in the treatment of measles, especially in high-risk populations. The scientific basis for its use dates back to the early and mid-20th century, when studies demonstrated that passive immunization with serum containing measles-specific antibodies could prevent or attenuate the severity of the disease if given within six days of exposure. This approach was particularly critical before the development of the measles vaccine in the 1960s.
Current guidelines from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommend immune globulin for post-exposure prophylaxis in certain groups, including infants too young for vaccination, pregnant women without evidence of immunity, and immunocompromised individuals. The rationale is that immune globulin provides immediate, although temporary, passive immunity through exogenous antibodies, helping to prevent measles or reduce its severity in those at greatest risk of complications.
While the introduction of the measles vaccine has greatly reduced the need for immune globulin, its use in specific settings is supported by decades of clinical data and ongoing expert recommendations. Its efficacy is highest when administered soon after exposure. Therefore, the use of Immunoglobulin G for measles is scientifically validated, with strong historical and contemporary evidence supporting its role in high-risk situations.